Ifinatamab deruxtecan
Phase 2 small_molecule active
Quick answer
Ifinatamab deruxtecan for Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) is a Phase 2 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo Europe GmbH
- Indication
- Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active